Kaptein Ad A
Medical Psychology Section, Leiden University Medical Centre, Leiden, Netherlands.
Patient Prefer Adherence. 2013 Jul 24;7:703-8. doi: 10.2147/PPA.S46990. Print 2013.
Administering growth-hormone therapy (GHT) is a long-term treatment, associated with avoidance and phobic behaviors in the children involved. The current study examined GHT users' perceptions of a new needle-free device (ZomaJet Vision X [10 mg/mL]) with a lower injection volume compared to the traditional device.
A total of 73 persons participated (mean age ± standard deviation, 10.10 ± 3.60 years) in a longitudinal design. Users' views were studied 4 weeks after having applied both the old and the new device for a period of at least 4 weeks. Satisfaction, ease and frequency of restitution, local sensations, bruises during administering GHT, affective response to local sensations, and subject preference were assessed on the basis of the users' responses.
Subjects' satisfaction with the new device was equal compared with the previous device for the total group of 73 children. However, the subgroup of 59 children who proved tolerant to meta-cresol (new preservative for Vision X only) reported a significantly higher satisfaction rating with the new device compared to the old device (7.7 vs 6.6, P=0.0002). Vision X was evaluated as better on ease and frequency of restitution and the number of bruises. Pain sensations did not differ meaningfully between the two devices. The new device was favored over the previous one in a majority of respondents. Vision X allows easy reconstitution of the solution, which was reflected in the percentage of young children able to prepare transjections themselves being more than doubled, illustrating the greater sense of empowerment in these users. Self-reported adherence to the therapy was good (less than 10% of injections missed) with both devices.
The new device ZomaJet Vision X appears to be evaluated more positively than the previous version on criteria that refect users' preferences.
生长激素疗法（GHT）是一种长期治疗方法，会使接受治疗的儿童出现回避和恐惧行为。本研究调查了生长激素疗法使用者对一种新型无针装置（ZomaJet Vision X [10 mg/mL]）的看法，该装置的注射量低于传统装置。
共有73人（平均年龄±标准差，10.10±3.60岁）参与了一项纵向研究。在使用新旧两种装置至少4周后4周，研究使用者的观点。根据使用者的回答，评估满意度、恢复的难易程度和频率、局部感觉、注射生长激素时的瘀伤情况、对局部感觉的情感反应以及受试者的偏好。
在73名儿童的总群体中，受试者对新装置的满意度与之前的装置相当。然而，在59名对间甲酚（仅为Vision X的新型防腐剂）耐受的儿童亚组中，与旧装置相比，新装置的满意度评分显著更高（7.7对6.6，P = 0.0002）。Vision X在恢复的难易程度和频率以及瘀伤数量方面被评价为更好。两种装置在疼痛感觉上没有显著差异。在大多数受访者中，新装置比之前的装置更受青睐。Vision X使溶液易于复溶，这体现在能够自己准备注射的幼儿比例增加了一倍多，说明这些使用者的自主感更强。两种装置的自我报告治疗依从性都很好（错过的注射少于10%）。
在反映使用者偏好的标准方面，新型装置ZomaJet Vision X似乎比之前的版本得到了更积极的评价。
